PMID- 36200308
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221013
IS  - 2234-1900 (Print)
IS  - 2234-3164 (Electronic)
IS  - 2234-1900 (Linking)
VI  - 40
IP  - 3
DP  - 2022 Sep
TI  - Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A 
      single-center experience.
PG  - 192-199
LID - 10.3857/roj.2022.00101 [doi]
AB  - PURPOSE: Ablative treatment of oligometastases has shown survival benefit with 
      certain tumors, although these effects still are to be demonstrated in prostate 
      cancer. MATERIALS AND METHODS: We analysed the toxicity and clinical control 
      results obtained in patients with bone-only oligometastatic prostate cancer 
      treated with stereotactic ablative radiotherapy (SABR). Retrospective study on 
      patients with metachronous oligoprogression and synchronous de novo bone-only 
      oligometastatic prostate cancer treated with SABR and androgen deprivation 
      therapy. RESULTS: Treatment schedules varied according to location and organs at 
      risk, with biologically equivalent dose (BED) >/=100 Gy. Fifty-five bone lesions 
      (31 patients) were treated and evaluated for toxicity, local control, 
      progression-free survival (PFS), and overall survival (OS). After a 41-month 
      follow-up, there was minimal acute or chronic toxicity and no G3 toxicity. The 
      local control at 3 and 5 years was 100% and 87.1%, respectively. Median PFS and 
      OS were 43 and 98 months, respectively. The best result in PFS was obtained with 
      BED >/=230 Gy, delaying time to the next systemic therapy by 28.5 months. 
      CONCLUSION: The use of SABR in bone oligometastases of prostate cancer is safe 
      with minimal toxicity and excellent results in local control and PFS, delaying 
      the start of the next systemic therapy.
FAU - Sanchez-Iglesias, Angel L
AU  - Sanchez-Iglesias AL
AD  - Department of Radiation Oncology, Consorcio Hospitalario Provincial de Castellon, 
      Spain.
FAU - Morillo-Macias, Virginia
AU  - Morillo-Macias V
AD  - Department of Radiation Oncology, Consorcio Hospitalario Provincial de Castellon, 
      Spain.
FAU - Santafe-Jimenez, Ana
AU  - Santafe-Jimenez A
AD  - Department of Radiation Oncology, Consorcio Hospitalario Provincial de Castellon, 
      Spain.
FAU - Ferrer-Albiach, Carlos
AU  - Ferrer-Albiach C
AD  - Department of Radiation Oncology, Consorcio Hospitalario Provincial de Castellon, 
      Spain.
LA  - eng
GR  - Castellon Provincial Hospital Foundation/
PT  - Journal Article
DEP - 20220927
PL  - Korea (South)
TA  - Radiat Oncol J
JT  - Radiation oncology journal
JID - 101577577
PMC - PMC9535412
OTO - NOTNLM
OT  - Bone oligometastases
OT  - Next systemic therapy
OT  - Prostate cancer
OT  - Stereotactic body radiotherapy
COIS- Conflict of Interest No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2022/10/07 06:00
MHDA- 2022/10/07 06:01
PMCR- 2022/09/01
CRDT- 2022/10/06 03:37
PHST- 2022/02/22 00:00 [received]
PHST- 2022/08/25 00:00 [accepted]
PHST- 2022/10/06 03:37 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/07 06:01 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - roj.2022.00101 [pii]
AID - roj-2022-00101 [pii]
AID - 10.3857/roj.2022.00101 [doi]
PST - ppublish
SO  - Radiat Oncol J. 2022 Sep;40(3):192-199. doi: 10.3857/roj.2022.00101. Epub 2022 
      Sep 27.